tailieunhanh - The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: In-vitro discovery and in-vivo validation

Docetaxel based therapy is one of the first line chemotherapeutic agents for the treatment of metastatic castrate-resistant prostate cancer. However, one of the major obstacles in the treatment of these patients is docetaxel-resistance. Defining the mechanisms of resistance so as to inform subsequent treatment options and combinations represents a challenge for clinicians and scientists. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN